🐦 推特Wall St EngineCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-31 04:05:38时区推断·⟳ 抓取 07-31 04:05:44·⚡ 决策 08-01 01:33:33 +21h27m·87.7 天前
Dexcom二季度业绩超预期但全年收入指引基本贴近预期，财报后反应已进入盘中消化阶段
二季度收入13.1亿美元、调整后EPS 0.70美元均高于预期，利润率表现强于营收端。
📄 原文Wall St Engine@wallstengine↗ 原文
DEXCOM $DXCM Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $1.31B (Est. $1.29B) 🟢; +13% YoY 🔹 Adj. EPS: $0.70 (Est. $0.61) 🟢; +4…
不做 Dexcom（DXCM.US）
财报方向偏正面但收入指引中点基本贴近预期，CONNECT核心催化已在6月公开，且当前已是次日盘中、股价已反应；stock_quote连续504，无法满足ENTER的行情确认要求，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司此前确认将于2026-07-30盘后发布二季度业绩并召开电话会，财报日期本身是日历事件。
- 社媒在美股盘后即时转述Dexcom二季度收入、EPS、EBITDA和全年指引数据。
- 次日盘中Dexcom（DXCM.US）约60.49美元、较前收59.33美元上涨约1.96%，显示财报已进入公开交易消化阶段。市场反应:DXCM.US盘中约+1.96%。
关键理由
- 二季度收入13.1亿美元、调整后EPS 0.70美元均高于预期，利润率表现强于营收端。
- 全年收入指引5.18亿至5.25亿美元区间的中点约52.15亿美元，基本贴近市场预期52.2亿美元，新增预期差主要来自利润率而非收入上修。
- 当前距财报发布已超过21小时，美股已进入次日盘中交易，Yahoo Finance显示Dexcom（DXCM.US）约60.49美元、日内仅上涨约1.96%，短线财报交易窗口已大部分消化。
主要风险
- CGM赛道仍面临Abbott Libre等竞争，单季利润率超预期不等于收入端持续加速。
- stock_quote两次504未能返回行情，最终只用Yahoo Finance网页行情辅助判断，不满足本系统对ENTER所需的行情工具确认。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB检索实际调用但服务504，未能提供可用于提高多头置信度的旧闻或敞口补充。
检索:Dexcom DXCM Q2 2026 earnings guidance consensus CONNECT trial risks competition Abbott CGM - 做多前查反向 · 来源 web · 日期 2026-07-16 · 影响 weakens
Abbott近期同样交出超预期业绩并上调全年EPS指引，Libre等竞品压力仍在，削弱Dexcom单季财报的独占性重定价空间。
检索:Dexcom Q2 2026 earnings Abbott competition price target July 2026 原文 ↗
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 1,031 字
DEXCOM $DXCM Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $1.31B (Est. $1.29B) 🟢; +13% YoY
🔹 Adj. EPS: $0.70 (Est. $0.61) 🟢; +46% YoY
🔹 Non-GAAP Operating Income: $328.3M (Est. $286M) 🟢; +48% YoY
🔹 Adjusted EBITDA: $421.3M (Est. $387M) 🟢
Raises FY26 Guide:
🔹 Revenue: $5.18B-$5.25B (Est. $5.22B) 🟡
🔹 Non-GAAP Gross Profit Margin: ~64%
🔹 Non-GAAP Operating Margin: ~23.5%-24%
🔹 Adjusted EBITDA Margin: ~31.5%-32%
Geographic Revenue:
🔹 U.S. Revenue: $933.4M; +11% YoY
🔹 International Revenue: $375.0M; +19% YoY
Other Q2 Metrics:
🔹 Organic Revenue Growth: +12% YoY
🔹 Non-GAAP Gross Margin: 64.1%; +400 bps YoY
🔹 GAAP Operating Margin: 24.3%; +590 bps YoY
Comments:
🔸 “we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity and introduced a new long-term financial outlook through 2030”
🔸 “This quarter’s performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan.”
🔹 Revenue: $1.31B (Est. $1.29B) 🟢; +13% YoY
🔹 Adj. EPS: $0.70 (Est. $0.61) 🟢; +46% YoY
🔹 Non-GAAP Operating Income: $328.3M (Est. $286M) 🟢; +48% YoY
🔹 Adjusted EBITDA: $421.3M (Est. $387M) 🟢
Raises FY26 Guide:
🔹 Revenue: $5.18B-$5.25B (Est. $5.22B) 🟡
🔹 Non-GAAP Gross Profit Margin: ~64%
🔹 Non-GAAP Operating Margin: ~23.5%-24%
🔹 Adjusted EBITDA Margin: ~31.5%-32%
Geographic Revenue:
🔹 U.S. Revenue: $933.4M; +11% YoY
🔹 International Revenue: $375.0M; +19% YoY
Other Q2 Metrics:
🔹 Organic Revenue Growth: +12% YoY
🔹 Non-GAAP Gross Margin: 64.1%; +400 bps YoY
🔹 GAAP Operating Margin: 24.3%; +590 bps YoY
Comments:
🔸 “we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity and introduced a new long-term financial outlook through 2030”
🔸 “This quarter’s performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。